Clinical Trial Update: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FOLFOX to Gemcitabine in metastatic pancreatic cancer patients not fit for FOLFIRINOX.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• FOLFOX
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Pancreatic Adenocarcinoma | Phase 3 | Status: UNKNOWN